-
Dec 31, 2024 | 
respiratory-research.biomedcentral.com | Athol U Wells |Ayodeji Adegunsoye |Vincent Cottin |Sonye Danoff |Anand Devaraj |Kevin Flaherty | +7 more
Surveys were completed between March 2022 and July 2023. The international guideline on the definition of PPF [1] was published between distribution of the first and second rounds of the survey. The first survey was sent to 405 physicians in 32 countries and completed by 207, of whom 131 completed the second round and 94 completed the third round. The clinical experience of the respondents is summarised in Table S1 in Additional file 1.
-
Dec 18, 2024 | 
bmcgenomics.biomedcentral.com | Min Hyung Ryu |Jeong Yun |Kangjin Kim |Michele Gentili |Auyon J Ghosh |Frank C. Sciurba | +10 more
465 subjects met the case criteria for COPD, 213 subjects met the case criteria for IPF, and 348 subjects met the control criteria. Demographic and clinical characteristics of the 1,026 subjects included in our analysis are shown in Table 1. Notably, IPF subjects were predominantly male (70%). The cohort included 90% of self-identified white subjects. COPD subjects were predominantly smokers (95.2% have ever smoked) and IPF and control subjects were 65.3% and 67.8% ever smokers, respectively.
-
Jul 20, 2024 | 
sports.yahoo.com | Kevin Flaherty
The first time the Kansas City Current played the Houston Dash this season, the two teams faced a more-than-three-hour lightning delay. But when the Dash visited CPKC Stadium for the NWSL x Liga MX Summer Cup Saturday night, the Current brought its own lightning strike. It took all of 59 seconds for Kansas City to change its goal tally, as Temwa Chawinga broke free and crossed to a streaking Michelle Cooper.
-
Jun 27, 2024 | 
bmjopenrespres.bmj.com | Kevin Flaherty |Kevin Brown |Athol U Wells |Emmanuelle Clerisme-Beaty
The PF-ILD trial (1199.247, NCT02999178) is a multicentre, prospective, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of nintedanib in patients with progressive fibrosing lung disease over 52 weeks. The study is conducted at specialised referral centres experienced in ILD management in approximately 15 countries of the Americas, Europe and Asia.
-
Jun 8, 2024 | 
kansascity.com | Kevin Flaherty
Kansas City Royals third baseman Adam Frazier (26) takes a swing during an at-bat against the Seattle Mariners at T-Mobile Park on May 15, 2024. USA TODAY Sports A day after the Kansas City Royals completed an eight-run comeback - in a game they never led until they walked it off in the ninth - Adam Frazier ensured they wouldn't have to wait nearly as long to pull ahead.
-
Jun 4, 2024 | 
emporiagazette.com | Kevin Flaherty
Before the Kansas City Royals shipped Aroldis Chapman to the Texas Rangers for Cole Ragans last June, they asked a question in a group-think setting:What is this guy missing? Royals pitching coach Brian Sweeney said the team noticed Ragans’ drastic uptick in velocity through work with Tread Athletics — Ragans’ threw his 2023 fastball 4.4 miles per hour harder, on average, than his 2022 version according to Baseball Savant — but the pitch profile wasn’t quite complete.
-
Jun 1, 2024 | 
kansascity.com | Kevin Flaherty
Kansas City Royals starting pitcher Cole Ragans (55) pitches against the Milwaukee Brewers during the second inning at Surprise Stadium on March 17, 2024. USA TODAY Sports Before the Kansas City Royals shipped Aroldis Chapman to the Texas Rangers for Cole Ragans last June, they asked a question in a group-think setting:What is this guy missing?
-
May 23, 2024 | 01684-x/abstract&sz=64)
jhltonline.org | Michael Combs |Elizabeth A. Belloli |Kevin Flaherty
KEYWORDSchronic lung allograft dysfunctionCLADpirfenidoneantifibrotic therapyclinical trialGet full text accessLog in, subscribe or purchase for full access. References1. Singer, J.P. ∙ Singer, L.G.Quality of life in lung transplantationSemin Respir Crit Care Med. 2013; 34:421-4302. Titman, A. ∙ Rogers, C.A. ∙ Bonser, R.S. ... Disease-specific survival benefit of lung transplantation in adults: a national cohort studyAm J Transplant. 2009; 9:1640-16493. Ofek, E. ∙ Sato, M. ∙ Saito, T. ...
-
Apr 14, 2024 | 
clinicalleader.com | Kevin Flaherty
Community-Driven Registries Drive Understanding Of Rare DiseasesIn an effort to increase and diversify research, the Pulmonary Fibrosis Foundation (PFF) envisioned a new approach to aggregating usable medical data — asking patients directly. Understanding Clinical Trial Patient AttritionKnowing why patients may choose to drop out of a study, such as adverse events, compliance, or external factors, can help sponsors and researchers create a strategy to keep them more engaged.
-
Mar 7, 2024 | 
clinicalleader.com | Kevin Flaherty
By Kevin Flaherty, MD, MS, steering committee chair, Pulmonary Fibrosis Foundation (PFF) Registry
Effective and impactful patient care is rooted in prior experience and research. Personal anecdotes, real-time information, and varied perspectives enable healthcare providers to make more informed decisions about how they provide optimal patient care.
